Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Dendreon To Make Major Job Cuts
by Lisa M. Jarvis
August 6, 2012
| A version of this story appeared in
Volume 90, Issue 32
Dendreon will cut 600 jobs, or roughly 40% of its workforce, and close its Morris Plains, N.J., manufacturing facility in an attempt to save roughly $150 million annually. Dendreon has struggled to become profitable since the 2010 approval of its prostate cancer immunotherapy, Provenge. Sales of Provenge totaled $80 million in the second quarter, down 2.4% from the first quarter, and the drug is expected to face fierce competition from new products in the coming months. Dendreon shed 500 workers in September 2011.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X